Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors

Next Previous
X
Search
Trial Profile

A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Fluorouracil (Primary) ; Lenvatinib (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Vibostolimab+pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Liver cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms KEYVIBE-005
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 01 Aug 2024 Planned End Date changed from 22 Feb 2027 to 12 Aug 2026.
    • 01 Aug 2024 Planned primary completion date changed from 22 Feb 2027 to 12 Aug 2026.
    • 01 Aug 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top